Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bio Q3 Revenues Increase 12 Percent

NEW YORK (GenomeWeb News) – Meridian Bioscience said today that sales in its fiscal third quarter rose 12 percent year over year.

For the three months ended June 30, the company has $47.1 million in sales, up from $41.9 million a year ago, edging out the average Wall Street estimate of $47.0 million.

In a statement, CEO John Kraeutler said that Illumigene product sales were up 36 percent year over year.

Profit was $10.2 million, or$.24 per share, compared to a profit of $8.6 million, or$.21 per share. Adjusted EPS was $.25, beating the average Wall Street estimate of $.22.

R&D was essentially flat at $2.7 million, while SG&A costs of $12.2 million was up 3 percent from $11.8 million a year ago.

Meridian Bio finished the quarter with $40.4 million in cash and equivalents.

The company declared a quarterly cash dividend of $.19 per share for the fiscal third quarter, payable on Aug. 15 to shareholders of record Aug. 5.

For the full-year, sales are expected to be in the range of $190 million to $194 million. EPS is expected in the range of $.86 and $.91.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.